Program
tedizolid phosphate
Also written as “TR-701 FA”, “Tedizolid phosphate” and “TR-701 FA 200 mg”.
Its studies are mostly in Skin Diseases, Bacterial · Bacterial Infections · Gram-Positive Bacterial Infections · Pneumonia · Skin Diseases, Infectious, led by 3 companies.
Drug pageTedizolid phosphate: every studyAll 29 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 250 open or running | phase 3since Jul 23, 2010 | Apr 23, 2008 | none ahead |
| Bayerits history only | 10 open or running | phase 3since Oct 18, 2013 | Oct 18, 2013 | none ahead |
| Dong-A ST | 10 open or running | phase 1since Mar 24, 2014 | Mar 24, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Dong-A ST only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 24, 2014First study: phase 1 study in HealthyFirst studyNCT02097043 · 31 enrolled · Korea, Republic of
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Bacterial 70S ribosome inhibitor”ChEMBL 37, by rule
Studies
The one study Dong-A ST leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02097043Healthy · Korea, Republic of | 1 | Completed | May 2014 | 31 |
How it is read
Names in the registry
- “TR-701 FA”, 9 entries
- “Tedizolid phosphate”, 2 entries
- “TR-701 FA 200 mg”, 2 entries
- “IV Tedizolid Phosphate”, 1 entry
- “Tedizolid Phosphate Oral Formulation 1 (Reference)”, 1 entry
Codes read as this program: TR701.
Conditions, from the studies’ own filings
- Skin Diseases, Bacterial, 3 studies
- Bacterial Infections, 3 studies
- Gram-Positive Bacterial Infections, 1 study
- Pneumonia, 1 study
- Skin Diseases, Infectious, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.